Comparing different radiation therapies for treating oligometastatic prostate cancer
Official title: Moderate Versus Ultra Hypofractionation or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment
Run by British Columbia Cancer Agency · NCT04610372 · Data updated 2026-11-12
This study is testing whether new types of radiation therapy can help men with oligometastatic prostate cancer feel better and live longer compared to standard treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 168 (estimated) |
| Sponsor | British Columbia Cancer Agency Academic / other |
| Drugs / interventions | radiation |
| Locations | 4 sites (Kelowna, British Columbia and 3 other locations) |
| Status | Recruiting |
| Started | July 12, 2021 |
| Main results expected | June 30, 2030 |
| Study ends | June 30, 2033 |
| Registry record updated | May 6, 2026 |
| Trial ID | NCT04610372 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men newly diagnosed with low volume oligometastatic prostate cancer, defined as fewer than 5 bone metastases and/or non-regional lymph node involvement.
✕Probably not a fit
Patients with a high metastatic burden, defined as 5 or more bone metastases or visceral metastases, will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness and tolerability of ultrahypofractionated stereotactic ablative radiotherapy (SABR) and brachytherapy compared to moderately hypofractionated external beam radiotherapy (EBRT) in men with oligometastatic prostate cancer. Participants will be randomized to receive one of the treatment options, and their urinary quality of life will be assessed alongside other secondary endpoints such as progression-free survival and overall survival. The trial aims to determine if the newer radiation techniques can provide similar or better outcomes while being more convenient and cost-effective.
Why it matters
Potential benefit: If successful, this study could offer a more effective and less burdensome treatment option for patients with oligometastatic prostate cancer.
How similar studies have gone: Other studies have shown promising results with similar approaches, but this specific comparison of ultrahypofractionation techniques is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Signed study specific informed consent * European Cooperative Oncology Group performance status 0 to 2 * Histologically confirmed adenocarcinoma of the prostate * Any Tumor stage, any T, any N, M1 * No prior therapy for prostate cancer apart from androgen deprivation * Planned for long-term androgen deprivation therapy (greater than 9 months in duration) * Patient is able and willing to complete the quality of life questionnaires, and other assessments that are a part of this study * For brachytherapy arms, patient must be technically suitable for brachytherapy according to investigator, in terms of bladder function and prostate size. Exclusion Criteria: * High metastatic burden defined as 5 or more bone metastases or visceral metastases * Contraindications to EBRT such as active inflammatory bowel disease or previous pelvic radiation * For Brachytherapy Arms =: Any prior Transurethral resection of prostate
Where it's running
-
British Columbia Cancer Agency Center for the Southern Interior
Kelowna, British Columbia, Canada Recruiting -
Vancouver Cancer Center
Vancouver, British Columbia, Canada Recruiting -
Vancouver Island Cancer Center
Victoria, British Columbia, Canada Recruiting -
Fraser Valley Cancer Center
Surrey, British Columbia, Canada Not yet recruiting
Study contacts
- Principal investigator: Juanita Crook, MD — BCCancer
- Study coordinator: Juanita Crook, MD
- Email: jcrook@bccancer.bc.ca
- Phone: 250 712 3958
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
This registry follows men with new, limited metastatic prostate cancer who receive targeted radiotherapy to the prostate and all visible metastases to see how they do over time in real-world care.
-
Comprehensive radiotherapy to all metastases plus primary prostate radiotherapy versus prostate-only radiotherapy for men with oligometastatic prostate cancer
This tests whether adding radiation to all PSMA-PET-visible metastases along with standard systemic therapy helps men with newly diagnosed oligometastatic prostate cancer stay progression-free longer than treating the prostate alone.
-
Maximal tumor eradication for patients with oligometastatic prostate cancer
This study is testing a new combination treatment for men with oligometastatic prostate cancer to see if it can improve their survival and quality of life.
-
Genomic biomarker-guided therapy for advanced prostate cancer
This study is testing if personalized treatment based on genetic markers can help men with advanced prostate cancer before surgery.
-
Combining immune therapy and radiation for prostate cancer treatment
This study is testing a new treatment that combines immune therapy drugs with targeted radiation to see if it helps men with a specific type of prostate cancer live longer and feel better.
-
Using Lu-PSMA with SABR for treating oligometastatic prostate cancer
This study is testing whether adding a special targeted therapy called Lu-PSMA to radiation treatment can help people with a few spots of prostate cancer live longer without their cancer getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.